Disease Spotlight
Agitation in Alzheimer's Dementia

Test Your Knowledge

Did you know?

Peer to Peer Insights
Profile Image
  • Add Media
  • Saved

7mo
Agitation in individuals with Alzheimer's disease: An assessment of behaviors using the cohen-mansfield agitation inventory in community-dwellers and impact on caregiver experience - PubMed

Agitation in individuals with Alzheimer's disease: An assessment of behaviors using the cohen-mansfield agitation inventory in community-dwellers and impact on caregiver experience - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40366088/

BackgroundAgitation is a common neuropsychiatric symptom of Alzheimer's disease; however, limited information exists on how measurable changes in agitated behaviors relate to overall caregiver experience. We sought to describe agitated...

This survey-based study used the Cohen-Mansfield Agitation Inventory to quantify agitated behaviors in Alzheimer's patients and linked greater agitation severity to higher caregiver burden, distress, and functional impairment.

  • Saved

7mo
Advancing Alzheimer's Research: Gender Differences, Cardiometabolic Risk, and Lifestyle Interventions.

At AAIC 2025, Dr. Heather Snyder, Senior Vice President of Medical and Scientific Relations at the Alzheimer's Association, highlights key findings on gender differences in Alzheimer’s disease, including women’s increased susceptibility following traumatic brain injury and the potential cognitive protection offered by managing cardiometabolic risk factors such as hypertension and diabetes.

Dr. Rachel Whitmer, Professor of Public Health Sciences and Neurology at UC Davis, presents results from the US POINTER study. This large-scale lifestyle intervention suggests that a structured program of diet, exercise, and cognitive engagement may delay cognitive aging over two years.

These insights underscore the importance of early, personalized, and holistic brain health strategies that span the entire adult lifespan.

  • Saved

7mo
Brief operationalized psychosocial interventions for agitation and psychosis: Use in clinical trials and clinical care - PubMed

Brief operationalized psychosocial interventions for agitation and psychosis: Use in clinical trials and clinical care - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40713414/

Although best practice guidelines universally recommend non-pharmacological interventions as the first-line treatment for neuropsychiatric symptoms, implementation has been limited. Several tools, such as Brief Psychosocial Therapy, are described which may...

This review highlights operationalized, non-pharmacological interventions—like personalized activities and social engagement—that reduce agitation in dementia, support psychotropic tapering, and improve quality of life, despite limited impact on psychosis.

  • Saved

7mo
Pre-psychosis in later life as a risk factor for progressive cognitive decline: Findings from the IPA psychosis in neurodegenerative disease working group - PubMed

Pre-psychosis in later life as a risk factor for progressive cognitive decline: Findings from the IPA psychosis in neurodegenerative disease working group - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40517113/

Pre-clinical Alzheimer's disease (AD) has traditionally been characterized by subtle cognitive deficits alongside biomarker changes. However, emerging evidence suggests a spectrum of neuropsychiatric changes, including apathy, affective disturbances, agitation, impulse...

This review links late-life pre-psychotic symptoms to early Alzheimer’s progression, emphasizing agitation and psychosis as key markers. It supports early screening and treatment to improve outcomes in dementia-related behavioral disturbances.

  • Saved

7mo
A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel - PubMed

A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40497644/

Following these recommendations for timely detection, accurate diagnosis, and appropriate management of agitation in patients with Alzheimer's dementia is likely to improve outcomes for most patients and caregivers.

Multispecialty experts offer U.S.-focused recommendations for diagnosing and managing agitation in Alzheimer’s dementia, highlighting individualized non-drug strategies and naming brexpiprazole as the only FDA-approved pharmacologic option.